NCT00910455已完成1 期
Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX246 Capsules in Healthy Adult Volunteers
Azevan Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 1
- 主要终点
- To assess safety and tolerability of SRX246 at single doses ranging between 20 and 360 mg
研究概览
简要总结
This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.
详细描述
This protocol represents the first in human study of SRX246, and is being conducted to begin to establish a safety profile, and collect human tolerability and pharmacokinetic data of orally administered SRX246.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and non-pregnant, non-lactating females of non-childbearing potential. Female patients should be either post-menopausal or surgically sterile.
- •Age ≥18 and ≤55 years.
- •Body mass index (BMI) of 18.5 to 34.0 kg/m2, inclusive, and a total body weight of >50kg (110 pounds).
- •In good health as determined by medical history, a baseline physical examination, vital signs, clinical laboratory tests and electrocardiogram (ECG) measurement.
- •Subject is willing and able to sign written informed consent prior to receipt of any study medication or beginning study procedures.
- •Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.
排除标准
- •Pregnant or lactating females, or females of childbearing potential.
- •Subject is positive for HIV, hepatitis B surface antigen or hepatitis C antibody tests at screening.
- •Subject with a positive urine test for drugs of abuse or alcohol at screening or at admission to the clinic on study Day -
- •Evidence of any out-of range laboratory value at screening that has not been reviewed, approved and documented as not clinically significant by the Principal Investigator.
- •Subject who has resting supine blood pressure outside of a systolic blood pressure range of 90-140 mmHg or a diastolic blood pressure outside a range of 50-90 mmHg on two consecutive measurements taken up to 10 minutes apart.
- •Subject who has resting supine pulse rate greater than 100 bpm or less than 50 bpm on two consecutive measurements taken up to 10 minutes apart.
- •Subject has taken any alcohol within 48 hours of ANY study-related activities AND cannot abstain from drinking alcohol during the entire duration of the subject's study participation.
- •Subject has used any tobacco products in the past 12 months.
- •A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis).
- •A general medical or psychological condition or behavior, including current substance dependence or abuse that, in the opinion of the investigator, might not permit the subject to complete the study or sign the informed consent.
- •Any clinically significant abnormality on screening 12-lead ECG (e.g., heart block, conduction disorders, ventricular and/or atrial arrhythmias).
- •Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Principal Investigator or the Physician Sub-Investigator, would make the subject unsuitable for the study or put them at additional risk.
- •Routine or PRN consumption of medications or herbal supplements that the subject is unable or unwilling to discontinue during the study.
- •Inability to understand or follow study instructions.
- •Treatment with an investigational drug within 30 days preceding the first dose of study medication.
- •Known allergy or hypersensitivity to the investigational study drug/placebo components.
研究组 & 干预措施
Active
Experimental
Single oral dose of SRX246 capsule
干预措施: SRX246 (Drug)
Placebo
Placebo Comparator
Single oral dose of placebo capsule
干预措施: Placebo (Drug)
结局指标
主要结局
To assess safety and tolerability of SRX246 at single doses ranging between 20 and 360 mg
时间窗: 24 hours
次要结局
- To assess Pharmacokinetics of SRX246 at single doses ranging between 20 and 360 mg(24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Multiple Dose Safety Study of SRX246 Capsules in Healthy VolunteersHealthyNCT01088932Azevan Pharmaceuticals24
已完成
1 期
Multiple Dose Safety Study of SRX251 Capsules in Healthy VolunteersHealthyNCT00532467Azevan Pharmaceuticals50
招募中
1 期
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1Radiation-Induced Xerostomia and HyposalivationNCT06714253RiboX Therapeutics Ltd.42
已完成
1 期
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With SchizophreniaSchizophreniaNCT04510298Sirtsei Pharmaceuticals, Inc.27
已完成
1 期
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy ParticipantsAlzheimer's DiseaseNCT04476303BeyondBio Inc.88